20/20 Biolabs (NASDAQ:AIDX) Issues Quarterly Earnings Results

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.12) earnings per share for the quarter, Zacks reports.

20/20 Biolabs Trading Down 9.4%

AIDX stock traded down $0.02 during midday trading on Monday, hitting $0.18. The company had a trading volume of 138,569 shares, compared to its average volume of 395,094. 20/20 Biolabs has a 52 week low of $0.18 and a 52 week high of $50.00. The stock’s 50 day moving average price is $0.35 and its 200 day moving average price is $0.95. The stock has a market cap of $2.47 million and a price-to-earnings ratio of -0.34.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised 20/20 Biolabs from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.00.

Check Out Our Latest Analysis on 20/20 Biolabs

20/20 Biolabs Company Profile

(Get Free Report)

20/20 BioLabs is a clinical laboratory company that has provided diagnostic testing services, with a focus on infectious diseases. Its offerings have included COVID-19 testing, such as molecular and antibody-based tests, along with related laboratory services. The company became known during the COVID-19 pandemic, when it supported demand for testing in the United States. Publicly available information about its broader operations and leadership is limited.

Read More

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.